Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Worm-Like Nanoparticles Used to Kill Breast Cancer Cells

By BiotechDaily International staff writers
Posted on 26 Dec 2013
Image: Microscope images of the worm-like, rod-like, micelle- and vesicle-shaped nanoparticles (Photo courtesy of University of New South Wales, Australia).
Image: Microscope images of the worm-like, rod-like, micelle- and vesicle-shaped nanoparticles (Photo courtesy of University of New South Wales, Australia).
Cylinder-shaped nanoparticles have been shown to be seven times more lethal than traditional spherical ones when delivering drugs to breast cancer cells, an international team of researchers has discovered.

Moreover, the worm-shaped drug delivery vehicles are not anymore toxic to healthy cells according to the study, which was published December 2013 in the journal Polymer Chemistry. In this study, different polymeric nanoparticle shapes (including spherical micelle, cylindrical micelle, and vesicles) were examined, and the early findings suggest shape plays an important role in the cell uptake and toxicity response. The project was co-led by Assoc. Prof. Cyrille Boyer, from the University of New South Wales (UNSW) School of Chemical Engineering (Sydney, Australia) and the Australian Center for NanoMedicine (Sydney), and Prof. Thomas Davis from Monash University (Melbourne, Australia), and involved Dr. Bunyamin Karagoz from Istanbul Technical University (Turkey).

Developing nanoparticles to target drugs directly to specific regions of the body is an increasing field of medicine, and these new findings suggest changing the shape of nanoparticles could slash both treatment costs and side effects. “What we’ve discovered is that a different shaped nanoparticle can have a very different effect on cancer cells, even with the same amount of drug,” said Dr. Boyer. “However there is still a lot of work to do and we need to test the nanoparticles in vitro with a range of cancer cells.”

Research had earlier mostly focused on spherical drug delivery systems as they are easier to make, but this new study additionally offers a simple and inexpensive approach to devising three different nanoparticle shapes: vesicular, spherical, and tubular or “worm-like.”

The researchers are now looking into whether cylindrical shape nanoparticles also deliver drugs more effectively to other types of cancers.

Related Links:

University of New South Wales School of Chemical Engineering
Monash University
Istanbul Technical University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.